 Additionally, the company expects mavrilimumab anti-GM-CSFRα Phase 2 data in giant cell arteritis GCA and KPL-404 anti-CD40 single-ascending-dose Phase 1 data in the fourth quarter of 2020. Focused corporate and clinical execution year-to-date has led to significant advancements across our pipeline, said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa. Following the receipt of Breakthrough Therapy designation and a Type B meeting with the U.S. FDA, we were able to pull forward the timeline for pivotal Phase 3 rilonacept data into the third quarter. 